High Density Lipoprotein (HDL)
| Availability | COMING SOON! Contact Us |
| Product Name | High Density Lipoprotein |
| Source | Human Plasma |
| Catalogue Number | 361-25 |
| Form | Liquid |
| Purity | > 95% (SDS-PAGE) |
| Protein | 1.0 - 5.0 in mg/mL (Lowry) |
| Total Cholesterol | Report mg/mL (Enzymatic) |
| Formulation | 0.2 micron filtered solution in 20 mM tris chloride, 150 mM sodium chloride and 0.01% EDTA, pH 7.4. |
| Storage | 2-8°C |
| Recertification | 1 year |
| Molecular Weight | 175,000-360,000 (Tetz second Edition) |
| Synonyms | HDL, HDL-C, HDL Concentrate, HDL Fraction, alpha-Lipoprotein |
| Country of Origin | United States |
Lee Biosolutions is world leader in the manufacturing of human plasma High Density Lipoprotein (HDL) and other cholesterol/triglyceride products for research and in vitro diagnostic (IVD) manufacturing uses.
Custom LDL/HDL and triglyceride ratios, technical support, bulk quantities and aliquoting available, email Info@leebio.com for more details.
OVERVIEW
High density lipoprotein, aka the “good cholesterol”, functions as the transit for cholesterol AWAY from blood, tissues, and organs of the body TO the liver where cholesterol breakdown occurs, ultimately helping to remove cholesterol from the arteries. Having HDL levels less than 40 mg/dL for men and less than 50 mg/dL for women is a major risk factor for heart disease.
HDL makes up 20%-30% of total cholesterol in the body, a combination of HDL, LDL, and triglycerides, which is typically measured through a blood test.
Total fasting cholesterol (no eating for 12 hours) should be measured once every five years, at the very least, beginning at the age of 20.
APPLICATIONS
- Diagnostic Controls, Calibrators & Standards
- Lipid Panels
- Infusion Therapy
- HDL-regression clinical trials
- Cardiac Research
- Immunoassays
- Research of HDL-raising drugs
- Cell culture
- Clinical chemistry
- Testing/assay validation
- Life Science
- ELISA, Blotting, etc.
- Characterization
- Manufacturing
EMERGING RESEARCH
- Recently, HDL has been found to be an important mediator in the reversal of metabolic dysfunction and the regression of cardiovascular disease due to atherosclerosis.
(Klancic, Woodward, Hofmann, & Fisher, 2016) - HDL infusions are being tested in clinical trials due to HDL’s ability to mediate the reversal of cholesterol transport. HDL infusions are isolated, partially delipidated HDL proteins and native apoAI or genetic variants such as apoAI Milano complexed with phospholipids. These agents have the potential to be applied to a vast range of vascular diseases, especially acute coronary syndromes.
(Kingwell & Chapman, 2013)
Lee Biosolutions, Inc
